US Stock MarketDetailed Quotes
AVDL Avadel Pharmaceuticals
- 11.170
- +0.020+0.18%
Close Nov 27 16:00 ET
- 11.170
- 0.0000.00%
Post 20:01 ET
1.08BMarket Cap-14893P/E (TTM)
11.320High11.000Low724.57KVolume11.210Open11.150Pre Close8.09MTurnover0.85%Turnover RatioLossP/E (Static)96.36MShares19.09052wk High14.41P/B949.21MFloat Cap10.41052wk Low--Dividend TTM84.98MShs Float43.600Historical High--Div YieldTTM2.87%Amplitude0.710Historical Low11.162Avg Price1Lot Size
About Avadel Pharmaceuticals Company
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Company Profile
SymbolAVDL
Company NameAvadel Pharmaceuticals
Listing DateJun 6, 1996
Issue Price10.39
Founded2015
CEOMr. Gregory J. Divis
MarketNASDAQ
Employees154
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code02
Phone353-1-901-5201
Websitehttp://www.avadel.com
Company Executives
- Name
- Position
- Salary
- Gregory J. Divis
- Director and Chief Executive Officer
- 985.20K
- Richard J Kim
- Chief Commercial Officer
- 770.95K
- Thomas S. Mchugh
- Chief Financial Officer and Principal Accounting Officer
- 663.14K
- Scott Macke
- Vice President, Supply Chain and Operations
- --
- Geoffrey M. Glass
- Non-Executive Chairman of the Board
- 482.34K
- Dr. Naseem S Amin, M.D.
- Independent Director
- --
- Dr. Mark A. Mccamish, M.D.,PhD
- Independent Director
- 449.84K
- Peter J. Thornton
- Independent Director
- 459.84K
- Linda S. Palczuk
- Independent Director
- 452.34K
- Dr. Eric J. Ende, M.B.A.,M.D.
- Independent Director
- 452.34K
- Jerad G. Seurer
- General Counsel and Corporate Secretary
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data